This is an implant for placement in the human body and an assembly for so placing that implant. Most desirably, it is an implant for use in the vasculature of the human body and is used to occlude some space in that vasculature as a portion of a treatment regimen. The implant itself is preferably a component of a deployment device using an electrolytically severable joint. The implant component is at least partially covered with a highly resistive or insulative covering. The highly resistive or insulative layer or covering appears to enhance the susceptibility of the electrolytic joint to quick erosion and thus detachment of the implant. Although the implant itself is preferably a vaso-occlusive device, it may instead be a stent, a vena cava filter, or other implant which may be installed in this manner. The implant may be independently coated with insulative or resistive material or may be formed using a material with such as tantalum, which forms such an insulator or resistor in situ.
|
1. A method for introducing an implant member into a selected space within the human body comprising:
placing an implant member via an attached core wire into the selected space, said implant member having a proximal end and a distal end and having an implant member core at least partially covered with an inorganic insulative covering comprising platinum, the implant member core being substantially covered with one of tantalum or zirconium, wherein the implant member further comprises an electrolytically severable joint attached to the implant member proximal end, the joint being relatively more susceptible to electrolysis in an ionic solution than is the implant member, and
electrolytically detaching the implant member from the core wire.
12. A method for occluding a selected space within a human body comprising:
placing the a tip of a catheter near the selected space,
introducing into a lumen of said catheter a tantalum an occluding member having a proximal end and a distal end and including an inner core comprising platinum, the inner core being substantially covered with one of tantalum or zirconium and further comprising an electrolytically severable joint attached to the occluding member proximal end, the joint being relatively more susceptible to electrolysis in an ionic solution than is the occluding member,
placing the occluding member into the space through the catheter tip, and
electrolytically severing the joint.
0. 21. A method for introducing an implant member into a selected space within the human body comprising:
placing an implant member via an attached core wire into the selected space, the core wire having a distal end comprising an electrolytically severable joint, said implant member comprising a proximal end and a distal end and a core formed from platinum, the core being substantially covered with one of tantalum and zirconium;
applying an electrical current to the core wire, wherein said current transforms the one of tantalum and zirconium into an insulative oxide in situ on an exterior surface of the implant member; and
detaching the implant member from the core wire at the electrolytically severable joint.
17. A method for occluding an aneurysm comprising:
placing the a tip of a catheter near the aneurysm via a blood vessel,
introducing into a lumen of the catheter a vaso-occlusive coil having a proximal end and a distal end and a highly resistive or insulative layer on at least a portion of the coil, the coil including an inner core comprising platinum, the inner core being substantially covered with one of tantalum and zirconium, the coil further comprising a sacrificial link attached to the coil proximal end, the link being relatively more susceptible to electrolysis in an ionic solution than is the coil, said link connected to a core wire,
advancing the coil through the catheter lumen, out the catheter tip and into the aneurysm, applying a positive electric current to the core wire to dissolve the link,; and
removing the core wire and catheter from the vessel.
0. 2. The method of
0. 3. The method of
0. 4. The method of
5. The method of claim 2 wherein the implant member comprises a core at least partially covered by an oxide-forming material 1, wherein at least 95% of the surface area of the implant member is covered with one of tantalum or zirconium.
9. The method of
0. 13. The method of
15. The method of
0. 18. The method of
0. 19. The method of
0. 22. The method of claim 21 wherein the implant member comprises a stent.
0. 23. The method of claim 21 wherein the implant member comprises a vena cava filter.
0. 24. The method of claim 21 wherein the implant member comprises a helically wound coil.
0. 25. The method of claim 24 wherein the coil further comprises a stretch resistant member extending at least partially from a proximal end of the coil to a distal end of the coil.
0. 26. The method of claim 25 wherein the stretch resistant member comprises polypropylene.
0. 27. The method of claim 21 wherein the implant member comprises a braid.
|
This application is a continuation reissue of U.S. reissue application Ser. No. 10/900,901, filed on Jul. 27, 2004 (now abandoned), which is a reissue application of U.S. application Ser. No. 09/668,033, filed on Sep. 21, 2000, now U.S. Pat. No. 6,425,914, which is a continuation of U.S. patent application Ser. No. 08/920,526, filed on Aug. 29, 1997, now U.S. Pat. No. 6,156,061 the entirety of which is hereby incorporated by reference.
This invention is an implant for placement in the human body and an assembly for so placing that implant. Most desirably, it is an implant for use in the vasculature of the human body and is used to occlude some space in that vasculature as a portion of a treatment regimen. The implant itself is preferably a component of a deployment device using an electrolytically severable joint. The implant component is at least partially covered with a highly resistive or insulative covering. The highly resistive or insulative layer or covering appears to enhance the susceptibility of the electrolytic joint to quick erosion and thus detachment of the implant. Although the implant itself is preferably a vaso-occlusive device, it may instead be a stent, a vena cava filter, or other implant which may be installed in this manner. The implant may be independently coated with insulative or resistive material or may be formed using a material with such as tantalum, which forms such an insulator or resistor in situ.
Implants may be placed in the human body for a wide variety of reasons. For instance, stents are placed in a number of different lumens in the body. They may be placed in arteries to cover vascular lesions or to provide patency to the vessel. Stents are also placed in biliary ducts to prevent them from kinking or collapsing. Grafts may be used with stents to promote growth of endotbelial tissue within those vessels.
Vena cava filters are implanted in the body, typically in the vena cava, to catch thrombus which are sloughed off from other sites within the body and which may be in the blood passing through the chosen site.
Vaso-occlusive devices or implants are used for a wide variety of reasons. They are often used for treatment of intra-vascular aneurysms. This is to say that the treatment involves the placement of a vaso-occlusive device in an aneurysm to cause the formation of a clot and eventually of a collagenous mass containing the vaso-occlusive device. These occlusions seal and fill the aneurysm thereby preventing the weakened wall of the aneurysm from being exposed to the pulsing blood pressure of the open vascular lumen.
Treatment of aneurysms in this fashion is significant improvement over the surgical method typically involved. The surgical or extravascular approach is a common treatment of intra-cranial berry aneurysm; it is straightforward but fairly traumatic. The method involves removing of portion of the cranium and locating the aneurysm. The neck of the aneurysm is closed typically by applying a specially sized clip to the neck of the aneurysm. The surgeon may choose to perform a suture ligation of the neck or wrap the entire aneurysm. Each of these procedures is performed by an very intrusive invasion into the body and is performed from the outside of the aneurysm or target site. General anesthesia, craniotomy, brain retraction, and a placement of clip around the neck of the aneurysm all are traumatic. The surgical procedure is often delayed while waiting for the patient to stabilize medically. For this reason, many patients die from the underlying disease prior to the initiation of the surgical procedure.
Another procedure—the extra-intravascular approach—involves surgically exposing or stereotaxically reaching an aneurysm with a probe. The wall of the aneurysm is perforated from the outside and various techniques are used to occlude the interior of the aneurysm to prevent its rebleeding. The techniques used to occlude the aneurysm include electro-thrombosis, adhesive embolization, hoghair embolization, and ferromagnetic thrombosis. These procedures are discussed in U.S. Pat. No. 5,122,136 to Guglielmi et al., the entirety of which is incorporated by reference.
Guglielmi et al. further describes an endovascular procedure which is at once the most elegant and least invasive. The procedure described in that patent includes a step in which the interior of the aneurysm is entered by the use of guidewire such as those in Engelson, U.S. Pat. No. 4,884,579 and a catheter as in Engelson, U.S. Pat. No. 4,739,768. These patents described devices utilizing guidewires and catheters which allow access to aneurysms from remote parts of the body. Typically, these catheters enter the vasculature through an artery in the groin. The Guglielmi et al system uses catheters and guidewires which have a very flexible distal regions and supporting midsections which allow the combinations to be steerable to the region of the aneurysm. That is to say that the guidewire is first steered for a portion of the route to the aneurysm and the catheter is slid up over that guidewire until it reaches a point near the distal end of the guidewire. By steps, the catheter and guidewire are then placed at the mouth of the aneurysm. The catheter is introduced into the aneurysm and vaso-occlusive or embolism-forming devices may be delivered through the lumen.
Various vaso-occlusive devices are introduced through the noted microcatheters to close the aneurysm site. In some instances, a small balloon may be introduced into the aneurysm where it is inflated, detached, and left to occlude the aneurysm. Balloons are becoming less in favor because of the difficulty in introducing the balloon into the aneurysm sac, the possibility of aneurysm rupture due to over-inflation of the balloon within the aneurysm, and the inherent risk associated with the traction produced when detaching the balloon.
Another desirable embolism-forming device which may be introduced into aneurysm using end of vascular placement procedure is found in U.S. Pat. No. 4,994,069 to Ritchart et al. In that patent are described various devices—typically platinum/tungsten alloy coils having very small diameters—which may be introduced into the aneurysm through a catheter such as those described in the Engelson patents above. These coils are often made of wire having a diameter of 2-6 mils. The coil diameter is often 10-30 mils. These soft, flexible coils, may be of any length desirable and appropriate for the site to be occluded. After these vaso-occlusive coils are placed in, e.g., a berry aneurysm, they first cause a formation of an embolic mass. This initial mass is shortly thereafter complemented with a collagenous material which significantly lessens the potential for aneurysm rupture.
There are variety of other vaso-occlusive devices, typically coils which may be delivered to the vascular site in a variety of ways, e.g., by mechanically detaching them from the delivery device. A significant number of these devices are described in patents owned by Target Therapeutics, Inc. For instance:
U.S. Pat. No. 5,234,437, to Sepetka shows a method of unscrewing a helically wound coil from a pusher having interlocking surfaces.
U.S. Pat. No. 5,250,071, to Palermo shows an embolic coil assembly using interlocking clasps both on the pusher and on the embolic coil.
U.S. Pat. No. 5,261,916, to Engelson shows a combination pusher/vaso-occlusive coil assembly joined by an interlocking ball and keyway type coupling.
U.S. Pat. No. 5,304,195, to Twyford et al., shows a pusher/vaso-occlusive coil assembly having a fixed proximally extending wire carrying a ball on its proximal end and a pusher having a similar end which two tips are interlocked and disengaged when expelled from the distal tip of the catheter.
U.S. Pat. No. 5,312,415, to Palermo shows a method for discharging numerous coils from a single pusher by using a guidewire which has a section capable of interconnecting with the interior of a helically wound coil.
U.S. Pat. No. 5,350,397, to Palermo et al. shows a pusher having a throat at its distal end and a pusher through its axis. The pusher throat holds onto the end of an embolic coil and releases that coil upon pushing the axially placed pusher wire against member found on the proximal end of the vaso-occlusive coil.
Other mechanically detachable embolism forming devices are known in the art.
Each of the patents listed herein is specifically incorporated by reference.
Guglielmi et al. shows an embolism forming device and procedure for using that device which, instead of a mechanical joint, uses an electrolytically severable joint. Specifically, Guglielmi et al. desirably places a finely wound platinum coil into a vascular cavity such as an aneurysm. The coil is delivered endovascularly using a catheter such as those described above. After placement in the aneurysm, the coil is severed from its insertion core wire by the application of a small electric current to that core wire. The deliverable coils are said to be made of a platinum material. They may be 1-50 cm or longer as is necessary. Proximal of the embolic coil, as noted above, is a core wire which is typically stainless steel. The core wire is used to push the platinum embolic coil into vascular site to be occluded.
Other variations of the Guglielmi et al. technology are found in U.S. Pat. No. 5,354,295.
None of the references described above teach or suggests an implant having a highly resistive or insulative layer on at least a portion of its exterior surface which is flexibly attached to an electrolytically severable delivery joint.
This invention is an implant which is at least partially coated with an insulative material. The implant may be a vaso-occlusive device, stent, vena cava filter, or any other implant which may be delivered via a catheter. Desirably, the device includes a core wire having a distal tip, which distal tip may be introduced into the selected site. The core wire is attached to the distal tip or implant in such a way that it may be electrolytically detached by application of a current to the core wire.
The improvement involves the use of an insulative or highly resistive covering on at least a portion of the implant. The resistive covering is preferably one which is formed in situ from the material making up the implant. This insulative or highly resistive layer appears to focus the current flow through the sacrificial electrolytic joint and thereby improves the rate at which detachment occurs.
As noted above, the Guglielmi et al. system for deploying an implant into the human body uses a core wire, an electrolytic sacrificial joint, and the implant to be deployed. A power supply is needed to provide power for electrolysis of the joint. The core wire is typically insulated on its outer surface from near the proximal end of the wire to the electrolytic sacrificial joint. The implant typically forms a portion of the circuit through the body. This invention substantially removes the implant itself from that circuit, thereby apparently focusing the current flow at the electrolytic joint where it is needed.
The most proximal end of core wire (110) is also left bare so that power supply (116) may be attached. The other pole of the power supply (116) is typically attached to a patch (118). The patch (118) is placed on the skin to complete the circuit from the power supply (116), through the core wire (110), through electrolytic joint (112), through the ionic solution in the body, and back to a patch (118) to the power supply (116). Other return routes may be used as the designer sees fit.
The coil making up this variation of the invention is generally of a diameter in the range of 0.00025 inches and 0.006 inches. Wire of such diameter is wound into a primary form having a diameter of between 0.003 and 0.025 inches. For most neurovascular indications, the preferable primary coil diameter is preferably between 0.008 and 0.018 inches.
The axial length of the primary coil will usually fall in the range of 0.5 to 100 cm, more usually 2.0 to 40 cm. Depending upon usage, the coil may well have 10-75 turns per centimeter, preferably 10-40 turns per centimeter. All of the dimensions here are provided only as guidelines and are not critical to the invention. However, only dimensions suitable for use in occluding sites within the human body are included in the scope of this invention.
Central to this invention is the provision of a highly resistive or insulative layer or covering on at least a portion of implant (120). Without wishing to be bound by theory, it is believed that the covering on implant (120) prevents or lessens current flow through the implant (120) itself and concentrates the current flow through the electrolytic joint (112). Preferably, implant (120) has at least 95% of its surface area covered with the layer. The layer, which will be discussed in more detail below, should not be of a type which interferes with the formation of the occlusion, when the implant is an occlusion device. It similarly should not interfere with the other functions inherent with this specific type of implant placed distally of the electrolytically severable joint (112). That is to say that, for instance, the insulative layer should not interfere with the function of a stent by, e.g., being thrombogenic.
The implant may be made of other insulation-forming materials or oxide forming materials including metals such as zirconium, its alloys, and related materials which form or may be made to form exterior resistive layers by, e.g., nitriding, or the like, preferably but not necessarily in situ.
Although the core (142) may be completely made of a insulation forming material as is shown in
Although the preferred variation of the invention is that found in
When the implant is a vaso-occlusive device, the shape of the device may be any of a number of suitable overall shapes to promote occlusion of the selected interior body space. In particular, when the implant is a helical coil, many shapes are known for treatment of particular abnormalities.
Each of the catheters described herein may also have attached fibrous materials to increase thrombogenicity.
The stent shown in
After the thrombus (218) has been formed and the aneurysm occluded, vaso-occlusive device (208) is detached from core wire (212) by electrolytic disintegration of sacrificial link (210).
After sacrificial link (210) is at least mostly dissolved by electrolytic action, typically in less than two minutes and most often in less than one minute, the core wire (212) and catheter (202) are removed from vessel (200) leaving aneurysm (206) occluded as shown in
This procedure is practiced under fluoroscopic control either with general or local anesthesia. A transfemoral catheter is typically used to treat cerebral aneurysms and is usually introduced at the groin. When the vaso-occlusive device (208) is insulated or covered with a highly resistive material as is contemplated this invention, it is not affected by electrolysis. When the core wire (212) and the pertinent portions of the supporting coils at the distal tip of the core wire (when utilized) are adequately coated with insulating coverings, only the exposed portion of the sacrificial link (210) is affected by the electrolysis.
Many alterations and modifications may be made by those having ordinary skill in this art without departing from the spirit and scope of the invention. The illustrative embodiments have been used only for the purposes of clarity and should not be taken as limiting the invention as defined by the following claims.
Wallace, Michael P., Roue, Chad C., Bashiri, Mehran
Patent | Priority | Assignee | Title |
10159490, | May 08 2015 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive devices |
10383635, | May 28 2014 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive devices and methods of use |
10639043, | Sep 19 2014 | DePuy Synthes Products, Inc. | Vasculature occlusion device detachment system with tapered corewire and heater activated fiber detachment |
10682497, | Dec 20 2013 | MicroVention, Inc. | Steerable guidewire system |
10722687, | Dec 20 2013 | MicroVention, Inc. | Segmented embolic system |
10729445, | Feb 09 2012 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive devices including a friction element |
10828037, | Jun 27 2016 | Covidien LP | Electrolytic detachment with fluid electrical connection |
10828039, | Jun 27 2016 | Covidien LP | Electrolytic detachment for implantable devices |
10874401, | Aug 08 2014 | Covidien LP | Electrolytic and mechanical detachment for implant delivery systems |
10925612, | May 08 2015 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive devices |
11051822, | Jun 28 2016 | Covidien LP | Implant detachment with thermal activation |
11633190, | May 28 2014 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive devices and methods of use |
11744992, | Dec 20 2013 | MicroVention, Inc. | Segmented embolic system |
11751880, | May 08 2015 | STRYKER EUROPEAN HOLDINGS I, LLC | Vaso-occlusive devices |
11839380, | Aug 08 2014 | Covidien LP | Electrolytic and mechanical detachment for implant delivery systems |
12064119, | Jun 27 2016 | Covidien LP | Electrolytic detachment for implantable devices |
9011482, | Feb 09 2012 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive devices including a friction element and methods of use |
9060777, | May 28 2014 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive devices and methods of use |
9254134, | Jan 21 2004 | Dendron GmbH | Device for implanting electrically isolated occlusion helixes |
9326774, | Aug 03 2012 | Covidien LP | Device for implantation of medical devices |
9717503, | May 11 2015 | Covidien LP | Electrolytic detachment for implant delivery systems |
9782178, | Sep 19 2014 | DEPUY SYNTHES PRODUCTS, INC | Vasculature occlusion device detachment system with tapered corewire and heater activated fiber detachment |
9808256, | Aug 08 2014 | Covidien LP | Electrolytic detachment elements for implant delivery systems |
9808599, | Dec 20 2013 | MICROVENTION, INC | Device delivery system |
9814466, | Aug 08 2014 | Covidien LP | Electrolytic and mechanical detachment for implant delivery systems |
9855050, | Sep 19 2014 | DEPUY SYNTHES PRODUCTS, INC | Vasculature occlusion device detachment system with tapered corewire and single loop fuse detachment |
9907557, | Feb 09 2012 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive devices including a friction element |
Patent | Priority | Assignee | Title |
4010759, | Aug 29 1975 | VITATRON MEDICAL B V , A CORP OF THE NETHERLANDS | Insulated, corrosion resistant medical electronic devices and method for producing same |
4739768, | Jun 02 1986 | STRYKER EUROPEAN HOLDINGS III, LLC | Catheter for guide-wire tracking |
4884579, | Apr 18 1988 | STRYKER EUROPEAN HOLDINGS III, LLC | Catheter guide wire |
4945342, | Oct 16 1987 | Instit Straumann | Electrical cable for performing stimulations and/or measurements inside a human or animal body and method of manufacturing the cable |
4994069, | Nov 02 1988 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusion coil and method |
5122136, | Mar 13 1990 | BLOSSOM FLOWER INC | Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5226911, | Oct 02 1991 | TARGET THERAPEUTICS, A DELAWARE CORPORATION | Vasoocclusion coil with attached fibrous element(s) |
5234437, | Dec 12 1991 | TARGET THERAPEUTICS, A DELAWARE CORPORATION | Detachable pusher-vasoocclusion coil assembly with threaded coupling |
5250071, | Sep 22 1992 | TARGET THERAPEUTICS, A DELAWARE CORPORATION | Detachable embolic coil assembly using interlocking clasps and method of use |
5261916, | Dec 12 1991 | TARGET THERAPEUTICS, A DELAWARE CORPORATION | Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling |
5304195, | Dec 12 1991 | TARGET THERAPEUTICS, A DELAWARE CORPORATION | Detachable pusher-vasoocclusive coil assembly with interlocking coupling |
5304200, | May 29 1991 | Cordis Corporation | Welded radially expandable endoprosthesis and the like |
5312415, | Sep 22 1992 | STRYKER EUROPEAN HOLDINGS III, LLC | Assembly for placement of embolic coils using frictional placement |
5350397, | Nov 13 1992 | TARGET THERAPEUTICS, A DELAWARE CORPORATION | Axially detachable embolic coil assembly |
5354295, | Mar 13 1990 | STRYKER EUROPEAN HOLDINGS III, LLC | In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5356433, | Aug 13 1991 | Cordis Corporation | Biocompatible metal surfaces |
5382259, | Oct 26 1992 | TARGET THERAPEUTICS, A DELAWARE CORPORATION | Vasoocclusion coil with attached tubular woven or braided fibrous covering |
5423829, | Nov 03 1993 | STRYKER EUROPEAN HOLDINGS III, LLC | Electrolytically severable joint for endovascular embolic devices |
5423849, | Jan 15 1993 | Target Therapeutics, Inc | Vasoocclusion device containing radiopaque fibers |
5522836, | Jun 27 1994 | STRYKER EUROPEAN HOLDINGS III, LLC | Electrolytically severable coil assembly with movable detachment point |
5540680, | Mar 13 1990 | STRYKER EUROPEAN HOLDINGS III, LLC | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5549624, | Jun 24 1994 | Target Therapeutics, Inc | Fibered vasooclusion coils |
5569245, | Mar 13 1990 | The Regents of the University of California | Detachable endovascular occlusion device activated by alternating electric current |
5582619, | Jun 30 1995 | STRYKER EUROPEAN HOLDINGS III, LLC | Stretch resistant vaso-occlusive coils |
5609629, | Jun 07 1995 | Cook Medical Technologies LLC | Coated implantable medical device |
5624449, | Nov 03 1993 | STRYKER EUROPEAN HOLDINGS III, LLC | Electrolytically severable joint for endovascular embolic devices |
5624461, | Jun 06 1995 | STRYKER EUROPEAN HOLDINGS III, LLC | Three dimensional in-filling vaso-occlusive coils |
5634942, | Apr 21 1994 | B. Braun Celsa | Assembly comprising a blood filter for temporary or definitive use and a device for implanting it |
5643254, | Mar 03 1994 | STRYKER EUROPEAN HOLDINGS III, LLC | Endovascular embolic device detachment detection method |
5645082, | Jan 29 1993 | SICHUAN JINJIANG ELECTRONIC SCIENCE AND TECHNOLOGY CO , LTD | Intravascular method and system for treating arrhythmia |
5645558, | Apr 20 1995 | Micrus Corporation | Anatomically shaped vasoocclusive device and method of making the same |
5649951, | Jul 25 1989 | Smith & Nephew Richards, Inc. | Zirconium oxide and zirconium nitride coated stents |
5733294, | Feb 28 1996 | Scion Medical Limited | Self expanding cardiovascular occlusion device, method of using and method of making the same |
5735896, | Aug 15 1994 | Biotronik | Biocompatible prosthesis |
5743905, | Jul 07 1995 | Regents of the University of California, The; Target Therapeutics, Inc | Partially insulated occlusion device |
5759161, | Apr 26 1996 | Kaneka Medix Corporation | Medical wire and method for leaving implanted devices |
5776178, | Feb 21 1996 | Medtronic, Inc | Medical electrical lead with surface treatment for enhanced fixation |
5782910, | Dec 21 1989 | Smith & Nephew, Inc. | Cardiovascular implants of enhanced biocompatibility |
5800454, | Mar 17 1997 | PRECISION VASCULAR SYSTEMS, INC | Catheter deliverable coiled wire thromboginic apparatus and method |
5824077, | Jan 19 1993 | SciMed Life Systems, INC; Boston Scientific Scimed, Inc | Clad composite stent |
5830230, | Mar 07 1997 | Board of Regents, The University of Texas System | Method of intracranial vascular embolotherapy using self anchoring coils |
5855578, | Mar 13 1990 | Regents of the University of California, The | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5873904, | May 16 1996 | Cook Medical Technologies LLC | Silver implantable medical device |
5891128, | Dec 30 1994 | STRYKER EUROPEAN HOLDINGS III, LLC | Solderless electrolytically severable joint for detachable devices placed within the mammalian body |
5891130, | Nov 13 1992 | Target Therapeutics, Inc. | Axially detachable embolic coil assembly |
5895385, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5895391, | Sep 27 1996 | Target Therapeutics, Inc | Ball lock joint and introducer for vaso-occlusive member |
5911717, | Mar 17 1997 | PRECISION VASCULAR SYSTEMS, INC | Catheter deliverable thrombogenic apparatus and method |
5916235, | Aug 13 1997 | The Regents of the University of California | Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities |
5919187, | Mar 13 1990 | The Regents of the University of California | Method and apparatus for endovascular thermal thrombosis and thermal cancer treatment |
5925037, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5925060, | Mar 13 1998 | B BRAUN CELSA; Scion Medical Limited | Covered self-expanding vascular occlusion device |
5925062, | Sep 02 1992 | Board of Regents, The University of Texas System | Intravascular device |
5928226, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5941888, | Feb 18 1998 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive member assembly with multiple detaching points |
5944714, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5947962, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries veins aneurysms vascular malformations and arteriovenous fistulas |
5947963, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5976126, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5976131, | Mar 13 1990 | The Regents of the University at California | Detachable endovascular occlusion device activated by alternating electric current |
6010498, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
6083220, | Mar 13 1990 | CALIFORNIA, UNIVERSITY OF, REGENTS OF THE, THEQ | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
6156061, | Aug 29 1997 | STRYKER EUROPEAN HOLDINGS III, LLC | Fast-detaching electrically insulated implant |
6174329, | Aug 22 1996 | Advanced Cardiovascular Systems, Inc. | Protective coating for a stent with intermediate radiopaque coating |
6425914, | Aug 29 1997 | STRYKER EUROPEAN HOLDINGS III, LLC | Fast-detaching electrically insulated implant |
EP719522, | |||
EP754435, | |||
EP826342, | |||
JP2641715, | |||
JP7265431, | |||
JP9108229, | |||
JP9168547, | |||
JP9232871, | |||
WO9723169, | |||
WO9748351, | |||
WO9802100, | |||
WO9804198, | |||
WO9804315, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Feb 14 2007 | Stryker Corporation | (assignment on the face of the patent) | / | |||
Feb 14 2007 | Stryker NV Operations Limited | (assignment on the face of the patent) | / | |||
Jan 03 2011 | Target Therapeutics, Inc | Stryker NV Operations Limited | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 025957 | /0313 | |
Jan 03 2011 | Target Therapeutics, Inc | Stryker Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 025957 | /0313 | |
Oct 13 2015 | Stryker NV Operations Limited | STRYKER MEDTECH LIMITED | NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS | 037153 | /0034 | |
Oct 13 2015 | STRYKER MEDTECH LIMITED | STRYKER EUROPEAN HOLDINGS I, LLC | NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS | 037153 | /0241 | |
Oct 13 2015 | STRYKER MEDTECH LIMITED | STRYKER EUROPEAN HOLDINGS I, LLC | CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT LISTED SERIAL NOS 09 905,670 AND 07 092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0241 ASSIGNOR S HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT EFFECTIVE DATE 9 29 2014 | 038043 | /0011 | |
Oct 13 2015 | Stryker NV Operations Limited | STRYKER MEDTECH LIMITED | CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL # 09 905,670 AND 07 092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0034 ASSIGNOR S HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT | 038039 | /0001 | |
Feb 26 2019 | STRYKER EUROPEAN HOLDINGS III, LLC | Stryker European Operations Holdings LLC | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 052860 | /0716 | |
May 19 2020 | STRYKER EUROPEAN HOLDINGS I, LLC | STRYKER EUROPEAN HOLDINGS III, LLC | NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS | 052861 | /0001 |
Date | Maintenance Fee Events |
May 06 2011 | ASPN: Payor Number Assigned. |
Jan 08 2014 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Apr 10 2015 | 4 years fee payment window open |
Oct 10 2015 | 6 months grace period start (w surcharge) |
Apr 10 2016 | patent expiry (for year 4) |
Apr 10 2018 | 2 years to revive unintentionally abandoned end. (for year 4) |
Apr 10 2019 | 8 years fee payment window open |
Oct 10 2019 | 6 months grace period start (w surcharge) |
Apr 10 2020 | patent expiry (for year 8) |
Apr 10 2022 | 2 years to revive unintentionally abandoned end. (for year 8) |
Apr 10 2023 | 12 years fee payment window open |
Oct 10 2023 | 6 months grace period start (w surcharge) |
Apr 10 2024 | patent expiry (for year 12) |
Apr 10 2026 | 2 years to revive unintentionally abandoned end. (for year 12) |